Neeraj Kohli

TL;DR: MM-121, a previously unidentified anticancer therapeutic designed using a systems approach, promises to benefit patients with combinatorial, ligand-induced activation of the ErbB signaling network that are not effectively treated by current therapies targeting overexpressed or mutated oncogenes.

TL;DR: A bispecific antibody suitable for both large scale production and systemic therapy by generating a single polypeptide fusion protein of two human scFv antibodies linked to modified human serum albumin, MM-111 is developed, effectively inhibiting ErbB3 signaling and showing antitumor activity in preclinical models that is dependent onErbB2 overexpression.

TL;DR: It is indicated that defect-specific posterior colporrhaphy is equal to or superior to traditional posterior colport rhaphy and is successful in restoring bowel function.

TL;DR: Although patients with suture ero-sion can be managed successfully with conservative treat-ment, patients with mesh erosion require surgical interven-tion, and transvaginal removal of the mesh with vaginal advancement appears to be an effective treatment in patients failing conservative management.

TL;DR: The comments regarding efficacy are based on a systematic review of the scientific literature from 1996–2011 conducted by the FDA, which yields some different conclusions regarding the safety and efficacy of mesh use in prolapse repair.